CA2514966A1 - Antiglucocorticoids for the treatment of postpartum psychosis - Google Patents

Antiglucocorticoids for the treatment of postpartum psychosis Download PDF

Info

Publication number
CA2514966A1
CA2514966A1 CA002514966A CA2514966A CA2514966A1 CA 2514966 A1 CA2514966 A1 CA 2514966A1 CA 002514966 A CA002514966 A CA 002514966A CA 2514966 A CA2514966 A CA 2514966A CA 2514966 A1 CA2514966 A1 CA 2514966A1
Authority
CA
Canada
Prior art keywords
glucocorticoid receptor
receptor antagonist
psychosis
alpha
postpartum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002514966A
Other languages
English (en)
French (fr)
Inventor
Joseph K. Belanoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2514966A1 publication Critical patent/CA2514966A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002514966A 2003-02-04 2004-02-04 Antiglucocorticoids for the treatment of postpartum psychosis Abandoned CA2514966A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44528403P 2003-02-04 2003-02-04
US60/445,284 2003-02-04
PCT/US2004/003183 WO2004069202A2 (en) 2003-02-04 2004-02-04 Antiglucocorticoids for the treatment of postpartum psychosis

Publications (1)

Publication Number Publication Date
CA2514966A1 true CA2514966A1 (en) 2004-08-19

Family

ID=32850982

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002514966A Abandoned CA2514966A1 (en) 2003-02-04 2004-02-04 Antiglucocorticoids for the treatment of postpartum psychosis

Country Status (6)

Country Link
US (1) US20040229855A1 (https=)
EP (1) EP1599208A4 (https=)
JP (1) JP2006516651A (https=)
AU (1) AU2004208842B2 (https=)
CA (1) CA2514966A1 (https=)
WO (1) WO2004069202A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008211613B2 (en) 2007-02-02 2013-05-23 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
CA2728563C (en) * 2008-07-01 2017-05-30 Corcept Therapeutics, Inc. Use of mifepristone for the treatment of amyotrophic lateral sclerosis
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
US11464764B2 (en) 2018-12-19 2022-10-11 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
WO2021242912A1 (en) 2020-05-27 2021-12-02 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
KR20250073629A (ko) 2022-10-06 2025-05-27 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제의 제형
US12433882B2 (en) 2022-10-28 2025-10-07 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468741A (en) * 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
AU747956B2 (en) * 1997-10-06 2002-05-30 Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction

Also Published As

Publication number Publication date
EP1599208A2 (en) 2005-11-30
EP1599208A4 (en) 2007-09-12
AU2004208842A1 (en) 2004-08-19
WO2004069202A3 (en) 2005-01-06
JP2006516651A (ja) 2006-07-06
US20040229855A1 (en) 2004-11-18
AU2004208842B2 (en) 2009-05-28
WO2004069202A2 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
US6362173B1 (en) Methods for treating psychosis associated with cocaine addiction with glucocorticoid receptor antagonists
CA2728563C (en) Use of mifepristone for the treatment of amyotrophic lateral sclerosis
US8476254B2 (en) Methods for treating psychosis associated with interferson-α therapy
EP1370268B1 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
EP2576582B1 (en) Treatment of muscular dystrophy
AU2004208842B2 (en) Antiglucocorticoids for the treatment of postpartum psychosis
US8097606B2 (en) Antiglucocorticoids for the treatment of catatonia
AU2003269898B2 (en) Methods for treating psychosis associated with interferon-alpha therapy
EP1726307A2 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued